L3VLUP
ProSign in

STVN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

STVNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • STVN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterSTVNJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 20212 holders, $23m40 holders, $24.1bn
Q4 20214 holders, $15m33 holders, $25.2bn
Q1 20223 holders, $13m35 holders, $28.2bn
Q2 20221 holders, $791k33 holders, $26.9bn
Q3 20221 holders, $847k36 holders, $25.4bn
Q4 20221 holders, $898k35 holders, $27.6bn
Q1 20232 holders, $47m42 holders, $24.5bn
Q2 20233 holders, $117m38 holders, $25.0bn
Q3 20233 holders, $108m37 holders, $18.9bn
Q4 20233 holders, $115m31 holders, $19.0bn
Q1 20245 holders, $194m32 holders, $19.7bn
Q2 20244 holders, $121m35 holders, $20.4bn
Q3 20243 holders, $128m28 holders, $22.3bn
Q4 20243 holders, $153m37 holders, $20.4bn
Q1 20253 holders, $141m32 holders, $20.5bn
Q2 20253 holders, $177m31 holders, $18.4bn
Q3 20253 holders, $193m32 holders, $23.7bn
Q4 20253 holders, $144m29 holders, $27.8bn
Q1 20264 holders, $96m34 holders, $35.6bn
Q2 20263 holders, $160m33 holders, $39.1bn
STVN

Stevanato Group S P A

Holders
3
Reported value
$128m
Buyers
2
Sellers
1

Breadth +1 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
28
Reported value
$22.3bn
Buyers
13
Sellers
16

Breadth -3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only STVN (2)

Artisan Partners LP, Moore Capital Management LP

Only JNJ (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Walleye Capital LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →